NCT06759714 "Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients"
| NCT ID | NCT06759714 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ain Shams University |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-11-23 |
| Primary Completion | 2025-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-11-23 with a primary completion date of 2025-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The role of epigenetic regulators and their dysregulation in cancer have gained much attention recently, as they influence the gene expression of many oncogenes and tumor suppressor genes. Non-coding RNAs (ncRNAs) including (lncRNAs and miRNAs) and chromatin remodeling machinery proteins are key epigenetic regulators playing a key role in carcinogenesis. In addition, they can serve as diagnostic and prognostic markers in many cancer types including breast cancer. Therefore, studying these molecular markers will help in the diagnosis and prognosis as well as in the better understanding of this devastating disease.To the best of our knowledge, This is the first research work measuring the expression level of UPK1A-AS1 and/or UNC5B-AS1 in breast cancer clinical samples. These data could provide a promising approach in introducing a novel markers that help in the diagnosis and prognosis of breast cancer and provide a potential targets for gene therapy.
Eligibility Criteria
Inclusion Criteria: Egyptian females breast cancer patients aged 18 years and above, newly diagnosed with breast cancer. Exclusion Criteria: Blood diseases, any cancer other than breast cancer, liver cirrhosis and uterine and urinary bladder diseases or breast cancer patients with any evidence of distant metastases.
Contact & Investigator
Sherihan Galal, phD
PRINCIPAL INVESTIGATOR
Ain Shams University
Frequently Asked Questions
Who can join the NCT06759714 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06759714 currently recruiting?
Yes, NCT06759714 is actively recruiting participants. Contact the research team at Dr.sherehan@pharma.asu.edu.eg for enrollment information.
Where is the NCT06759714 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06759714 clinical trial?
NCT06759714 is sponsored by Ain Shams University. The principal investigator is Sherihan Galal, phD at Ain Shams University. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.